Tumor mutational load predicts survival after immunotherapy across multiple cancer types
2019 · Nature Genetics · 4,300 citations
https://doi.org/10.1038/s41588-018-0312-8
A
Alexander N. Shoushtari
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
382
Papers
22.8K
Citations
53
h-index
124
i10-index
Alexander N. Shoushtari is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Melanoma and MAPK Pathways. The author has an h-index of 53, co-authored 325 publications.
ORCID: 0000-0002-8065-4412Papers by this author
worksMutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
2017 · Nature Medicine · 3,415 citations
https://doi.org/10.1038/nm.4333
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
2021 · New England Journal of Medicine · 828 citations
https://doi.org/10.1056/nejmoa2103485
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
2017 · Journal of Clinical Oncology · 617 citations
https://doi.org/10.1200/jco.2016.67.9258
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
2021 · Nature Communications · 440 citations
https://doi.org/10.1038/s41467-021-20935-9
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
2016 · Cancer · 367 citations
https://doi.org/10.1002/cncr.30258
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat